Reviva Pharmaceuticals Announced That The Last Patient In Its Phase 3 RECOVER Study Of Brilaroxazine For Schizophrenia Has Now Completed The Study. Topline Data Are Expected In October 2023
Portfolio Pulse from Benzinga Newsdesk
Reviva Pharmaceuticals has announced the completion of its Phase 3 RECOVER study of Brilaroxazine for schizophrenia. The topline data from the study is expected to be released in October 2023.
September 25, 2023 | 10:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reviva Pharmaceuticals' completion of its Phase 3 RECOVER study could potentially impact its stock positively, pending the results of the study due in October 2023.
The completion of a Phase 3 study is a significant milestone for any pharmaceutical company. This could potentially lead to a new product launch if the results are positive, which could significantly boost the company's revenues and, consequently, its stock price. However, the actual impact will depend on the results due in October 2023.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100